Search

ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment

Media

The approval is based on the pivotal phase III ATLAS and FLAIR studies that included more than 1,100 patients from 16 countries.

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-fda-approval-of-cabenuva-cabotegravir-rilpivirine-the-first-and-only-complete-long-acting-regimen-for-hiv-treatment/

First published: 21 January 2021

GSK publishes 2009 Corporate Responsibility Report

Media

In its 2009 Corporate Responsibility Report published online today, GSK reiterated its commitment to running its business responsibly.

https://www.gsk.com/en-gb/media/press-releases/gsk-publishes-2009-corporate-responsibility-report/

First published: 15 March 2010

GlaxoSmithKline and Human Genome Sciences announce topline 76-week results of phase 3 trial of Benlysta™ in systemic lupus erythematosus

Media

GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) and today announced topline secondary endpoints from BLISS-76.

https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-announce-topline-76-week-results-of-phase-3-trial-of-benlysta-in-systemic-lupus-erythematosus/

First published: 19 April 2010